Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
- Conditions
- Leukemia, Myeloid, AcuteStem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic SyndromesLymphoma, Non-Hodgkin
- Interventions
- Behavioral: Mindfulness Meditation (MM)Behavioral: Mindfulness-based Music Therapy (MBMT)
- Registration Number
- NCT05968963
- Lead Sponsor
- University of Miami
- Brief Summary
The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- ≥ 18 years of age
- have a primary diagnosis of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or non Hodgkin's Lymphoma (NHL)
- have a treatment plan for an allogeneic hematopoietic stem cell transplant
- Speak English or Spanish
- history of severe psychiatric illness (e.g., psychosis, active suicidality, inpatient treatment in the past 12 months)
- severe cognitive impairment (per the short portable mental status questionnaire)
- hearing impairment
- active alcohol or substance dependence within the past six months
- participated in music therapy or mindfulness programs in the past six months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mindfulness Meditation (MM) Mindfulness Meditation (MM) Participants will be in the MM group for 5 months. Mindfulness-based Music Therapy (MBMT) Mindfulness-based Music Therapy (MBMT) Participants will be in the MBMT group for 5 months.
- Primary Outcome Measures
Name Time Method Count of Participants Recruited Baseline (T1) Recruitment will be measured by the count of participants successfully recruited and randomized into the study.
Satisfaction Scores as Measured by Weekly Rating Satisfaction Score Up to 100 days post-transplant Scores per item range from 0 to 5. Higher scores indicate more satisfaction.
Number of Participants Retained Up to 18 months Participant retention will be examined via the number of participants retained in the study.
Mean Number of Intervention Sessions that Participants Completed Up to 100 days post-transplant Participant engagement will be examined via the mean number of intervention sessions completed by participants measured after the 8th (and last) intervention session which is given between 75 and 100 days post-transplant.
- Secondary Outcome Measures
Name Time Method Change in Immunocompetence as Measured by Thymic Function Baseline (T1), up to 18 months Thymic function T-cell receptor excision circles (TRECs) measured by TRECs/microliter.
Change in Immunocompetence as Measured by Regulatory T cells Baseline (T1), up to 18 months Regulatory T cells measured as cells/mm\^3
Change in Health Related Quality of Life Scores as Measures by Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) Baseline (T1), up to 18 months FACT-BMT score range 0-164, with higher scores indicating better quality of life.
Change in Fatigue as Measured by patient reported outcome measures (PROMIS®) Fatigue scale. Baseline (T1), up to 18 months (PROMIS®) Fatigue scale is scored on a range of 8 to 40. Higher scores indicate higher fatigue.
Number of Days of Hospitalization Measured from Admission to Engraftment. Up to 18 months To measure the number of days of hospitalization we will extract from the electronic medical record (EMR) days of hospitalization from admission to engraftment.
Number of Hospital Readmissions after Hospital Discharge Up to 100 days To measure the number of hospital readmissions we will extract from the electronic medical record (EMR) the number of hospital readmissions from hospital discharge.
Number of Infections from Hospital Admission up to 100 Days Post-Infusion Day To measure the number of infections we will extract from the electronic medical record (EMR) the number of infections from hospital admission measure up to 100 days post infusion.
Change in anxiety Scores as Measured with the Generalized anxiety disorder (GAD-7) Baseline (T1), up to 18 months Generalized anxiety disorder (GAD-7) range is 0 to 21; higher score is associated with more severe anxiety.
Change in Sleep Quality Scores as Measured by Pittsburgh Sleep Quality Index Baseline (T1), up to 18 months Pittsburgh Sleep Quality Index score range from 0 to 21. Higher score indicate worse sleep quality.
Number of Days to Engraftment Measured from Infusion to Engraftment. Up to 18 months To measure the number of days to engraftment we will extract from the electronic medical record (EMR) days from infusion to engraftment.
Change in Cancer-specific Distress Scores as Measured by the Impact of Events Scale-Revised Baseline (T1), up to 18 months Impact of Events Scale-Revised range is 0 to 88; higher score is associated with more effect caused by events.
Change in Immunocompetence as Measured by Cytokines Baseline (T1), up to 18 months Cytokines levels are measured in pg/mL. Any values outside of the normal range are associated with inflammation
Changes in Depression Scores as measured with the patient health questionnaire (PHQ-9) Baseline (T1), up to 18 months PHQ-9 (patient health questionnaire) score range is from 0 to 27; higher score is associated with more severe depression.
Change in Serum Cortisol as Measured by ELISA Baseline (T1), up to 18 months Serum cortisol levels are measured via ELISA. Serum Cortisol normal levels morning range: 10-20 mcg/dL ; afternoon range: 3-10 mcg/dL. Any values outside of the range are associated with higher stress and inflammation
Change in Pain as Measured by patient reported outcome measures (PROMIS®) pain scale. Baseline (T1), up to 18 months (PROMIS®) pain scale is scored on a range of 3 to 15 with higher scores indicating higher pain.
Change in Cognitive Function Scores as Measured by The Repeatable Battery for the Assessment of Neuropsychological Status. Baseline (T1), up to 18 months The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores range from 40-160 with higher scores indicating better cognitive function.
Trial Locations
- Locations (1)
University of Miami
🇺🇸Miami, Florida, United States